NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

You are seriously underestimating the power of the regulation of DCVAXL

Novocure (NVCR) – Has a $5B+ market cap despite questionable efficacy in GBM.
ImmunoGen (IMGN) – Jumped to $4B-$5B on approval and was later bought out for $10B.
Axsome (AXSM) – Hit $3B+ on a depression drug approval (not even an oncology breakthrough).

If NWBO captures just 10-20% of the $3B-$5B GBM market, that’s $300M-$1B in potential annual revenue. Even at a conservative 5x price-to-sales (P/S) ratio, NWBO would be valued at $1.5B-$5B based on revenue potential alone. Short Squeeze & Retail Demand

NWBO has a large retail investor base that has been holding for years. If approval triggers massive buying and short covering, a spike to $2B-$3B market cap could happen quickly.